| My Account | Subscribe | Contact Us | Donate |
Home
- The Edmonton Protocol and Me
- Olympia Dukakis and Her Husband Tackle Type 2
- Surfing with Type 1
- Behind the Wheel, But Still in Control
You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View
If you are a physician, educator and medical professional who focus on the treatment of diabetes, then this is the must have resource for you.
Finally! A fresh take on the “professional” journal. Each bi-monthly issue cuts through the jargon and presents the most important information you need to enhance your practice and assist your patients.
Each bi-monthly issue of Diabetes Health Professional is a self-contained handbook covering products, educational resources and the latest diabetes research, complimented by balanced editorial focused on medical news, drug prescription information, clinical practice recommendations and changing treatment options.
Each quarter we send you the latest, most updated research guides, product guides and educational resource guides available for you and your patients.
Each week the Diabetes Health E-Newsletter delivers links to the very latest in news, reviews, blogs and videos from Diabetes Health direct to your inbox.
As a subscriber you'll get access to the amazing Diabetes Health Digital Advantage™ so you can read the current issue of Diabetes Health magazine online wherever you are!
You can cancel your newsletter subscription at anytime by clicking "Unsubscribe" on the bottom of any newsletter you receive
Then enter your new email address in the above form and click "Subscribe"
Latest Insulin Articles
Pfizer Halts Sales of Exubera In Wake of Lung Cancer Fears
In wake of news that its inhaled insulin product Exubera has been linked to lung cancer, Pfizer Inc. has announced that it will cease manufacturing the drug and update labels on the remaining product to carry a cancer warning.
The company revealed that in a study of 4,740 patients taking Exubera, six developed lung cancer (1 out of every 780). In comparison, one out of 4,292 patients in the study who were not taking Exubera developed lung cancer.
Pfizer introduced Exubera in 2006 as the first inhaled insulin product on the market. By 2007, however, the company announced that it would cease marketing the product because of low demand. An estimated 4,000 people with diabetes worldwide are taking the drug.
Before receiving FDA approval to market Exubera, the drug’s apparent effects on lung function had been noted in studies – a concern that delayed approval for several years.
Inhaled insulin has been a kind of Holy Grail for pharmaceutical manufacturers since it avoids the pain and inconvenience of needle injections. When Pfizer ceased marketing Exubera last year, Novo Nordisk and Eli Lilly soon dropped their inhaled insulin development programs.
Valencia, Calif.-based MannKind Corp. has said it will continue work on its Technosphere inhaled insulin product.
Addendum:
Oramed Begins Studies on Oral Insulin Capsule
Israeli company Oramed Pharmaceuticals, Inc., a developer of oral delivery systems, has commenced Phase 2A studies on its oral insulin capsule at the Hadassah Medical Center in Jerusalem. The trial will focus on assessing the safety and efficacy of the capsule on 10 type 2 diabetes patients. This study is a continuation of the recently successfully completed Phase 1 studies in Israel.
Categories: Insulin, Type 1 Issues, Type 2 Issues
Facebook
MySpace 
Digg
You May Also Be Interested In...
Click Here To View Or Post Comments
Apr 17, 2008 -
Email to a Friend
Send a link to this page to your friends and colleagues.